找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Applied Peritoneal Dialysis; Improving Patient Ou Anjay Rastogi,Edgar V. Lerma,Joanne M. Bargman Book 2021 Springer Nature Switzerland AG 2

[复制链接]
楼主: FROM
发表于 2025-3-28 17:31:19 | 显示全部楼层
ESKD Complications: CKD-MBD, and phosphorus by altering the production of calcitriol, PTH, FGF-23, and klotho. Eventually these compensatory responses become unable to maintain normal mineral homeostasis, resulting in (1) altered serum concentrations of calcium, phosphorus, PTH, calcitriol, FGF-23, and klotho, (2) disturbances
发表于 2025-3-28 21:30:50 | 显示全部楼层
Peritoneal Dialysis in Diabetic Patients, new-onset diabetes. For those with pre-existing diabetes, worsening of diabetic control seems uncommon, unless the patient needs hypertonic cycles. Non-glucose-based PD solution may make diabetic control easier in some patients.
发表于 2025-3-29 01:30:33 | 显示全部楼层
发表于 2025-3-29 04:50:18 | 显示全部楼层
发表于 2025-3-29 08:15:00 | 显示全部楼层
发表于 2025-3-29 14:31:42 | 显示全部楼层
Entzinkung von Gichtstaub im Schmelzzyklonxia-inducible factor-prolyl hydroxylase inhibitors). Finally factors unique to PD are discussed to crystalize the unique challenges and opportunities inherent in treating ESKD-associated anemia in PD patients.
发表于 2025-3-29 18:03:46 | 显示全部楼层
History of Peritoneal Dialysis,p an appreciation for the amount of research, innovation, and perseverance that lead to the current status of PD. This chapter will outline the history of PD and review a number of major scientific breakthroughs that have collectively shaped how PD is currently practiced.
发表于 2025-3-29 20:38:26 | 显示全部楼层
The Evolution of Peritoneal Dialysis Solutions,lysate. The durability of PD as a dialysis modality depends on the type of solution utilized and its long-term effects on the peritoneal membrane. Many have argued that biocompatible solutions are ideal because they are proposed to limit the long-term degradation of the peritoneal membrane.
发表于 2025-3-30 01:05:40 | 显示全部楼层
发表于 2025-3-30 07:54:22 | 显示全部楼层
Anemia Management in Peritoneal Dialysis,xia-inducible factor-prolyl hydroxylase inhibitors). Finally factors unique to PD are discussed to crystalize the unique challenges and opportunities inherent in treating ESKD-associated anemia in PD patients.
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-5-1 15:38
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表